Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial

Mahbod Ebrahimi, Firoozeh Akbari Asbagh, Fatemeh Davari Tanha, Hamideh Pakniat, Elham Feizabad, Yasin Rasouli
International journal of reproductive biomedicine · 2022 · vol. 20(6) , pp. 483–490 · doi:10.18502/ijrm.v20i6.11444 · PMID:35958963 · W4285006310
article OA: gold CC0 ⤵ 2 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

Letrozole co-treatment in IVF cycles for women with endometriosis reduced gonadotropin dosage and estradiol levels without affecting pregnancy rates compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This double-blind randomized clinical trial studied infertile women with endometriosis to evaluate the co-treatment of gonadotropin and letrozole, compared within the randomized design. The investigators reported outcomes related to fertility treatment response under this combined hormonal regimen. The paper’s publicly provided information does not include participant numbers, specific outcome measures, or the explicit effect sizes, limiting the ability to characterize the magnitude and statistical significance of the findings. This paper is centrally about endometriosis — it tests gonadotropin plus letrozole co-treatment in infertile women with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: The common causes of infertility in women with endometriosis are folliculogenesis alternation, steroidogenesis and fertilization impairment, oocyte and embryo quality reduction, and implantation defect. Objective: To compare in vitro fertilization (IVF) cycle success rates of women with endometriosis who were treated with letrozole + gonadotropin (LA) vs. placebo + gonadotropin (PA). Materials and Methods: This double-blind, randomized clinical trial study was conducted with 94 infertile women with endometriosis (47 in the LA group and 47 in the PA group) who were candidates for IVF, from April-June 2021. For all participants, the long agonist protocol was applied. In both groups, gonadotropin-releasing hormone agonist was prescribed in the mid-luteal stage and from the third day of the cycle, and gonadotropin was started and its doses were regulated based on the patient's age, serum anti-Mullerian hormone and follicle-stimulating hormone. From the third day of the menstrual cycle, 5 mg of letrozole daily for 5 days was prescribed for the LA group, while the placebo was prescribed for the PA group on the identical days and duration. After embryo transfer, biochemical and clinical pregnancy were measured in the 2 groups. Results: 0.01) and estradiol level (p = 0.02) on the human chorionic gonadotropin administration day were significantly lower in the LA group compared with in the PA group. Fetus transfer was done for 32 women. No significant differences were detected between the study groups regarding biochemical or clinical pregnancy (p = 0.72 for both). Conclusion: Letrozole as a co-treatment drug in the IVF cycle of women with endometriosis can significantly reduce the gonadotropin dosage and estradiol level with the same pregnancy rates.
Full text 1,929 characters · extracted from oa-html · click to expand
Publication International Journal of Reproductive BioMedicine (IJRM) Record type Journal article Published 6 July 2022 Authors Mahbod Ebrahimi | Firoozeh Akbari Asbagh | Fatemeh Davari Tanha | Hamideh Pakniat | Elham Feizabad | Yasin Rasouli The publisher of this work supports multiple resolution. The work is available from the following locations: {'doi': '10.18502/ijrm.v20i6.11444', 'member_id': '7770', 'member': 'Knowledge E DMCC', 'container-title': 'International Journal of Reproductive BioMedicine (IJRM)', 'primary-resource': 'https://knepublishing.com/index.php/ijrm/article/view/11444', 'tld': 'knepublishing.com', 'clearbit-logo': '/static/no_logo.svg', 'coaccess': [], 'multiple-resolution': [{'url': 'https://ijrm.ssu.ac.ir/article-1-2271-en.html', 'tld': 'ssu.ac.ir', 'clearbit-logo': '/static/no_logo.svg'}, {'url': 'https://knepublishing.com/index.php/ijrm/article/view/11444', 'tld': 'knepublishing.com', 'clearbit-logo': '/static/no_logo.svg'}], 'type': 'JOURNAL ARTICLE', 'published_date': '6 July 2022', 'publication': 'International Journal of Reproductive BioMedicine (IJRM)', 'title': 'Co-treatment of gonadotropin and letrozole in infertile women with endometriosis: A double-blind randomized clinical trial', 'name': None, 'id': None, 'location': None, 'display_doi': 'https://doi.org/10.18502/ijrm.v20i6.11444', 'grant_info': None, 'grant_info_funders': None, 'grant_info_funder_ids': '', 'grant_info_type': None, 'multiple_lead_investigators': [], 'multiple_co_lead_investigators': [], 'multiple_investigators': [], 'finances': [], 'project_description': None, 'award_amount': None, 'award_start': None, 'funding_scheme': None, 'internal_award_number': None, 'editors': None, 'authors': 'Mahbod Ebrahimi | Firoozeh Akbari Asbagh | Fatemeh Davari Tanha | Hamideh Pakniat | Elham Feizabad | Yasin Rasouli', 'chairs': None, 'supplementary_ids': None} https://doi.org/10.18502/ijrm.v20i6.11444 JSON XML

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-04T00:34:36.779044+00:00
License: CC0 · commercial use OK